Switch to: Citations

Add references

You must login to add references.
  1. Consent to open label extension studies: some ethical issues.P. Wainwright - 2002 - Journal of Medical Ethics 28 (6):373-376.
    A frequent feature of pharmaceutical research is the open label extension study, in which patients participating in double blind placebo controlled trials of new medications are invited, on completion of the initial trial, to take the study drug for some further period. Patients are openly given the active substance at this stage, regardless of their assignment in the initial trial. Investigators are typically reluctant to unblind the patients’ assignment at the point of entry into the open label phase, on the (...)
    Download  
     
    Export citation  
     
    Bookmark   6 citations  
  • The Ethical Problems of the Open Label Extension Study.Kenneth Craig Micetich - 1996 - Cambridge Quarterly of Healthcare Ethics 5 (3):410.
    The institutional review board Is charged with assessing the risks and benefits of research projects Involving human subjects. Ethical considerations and federal regulations require that an IRB, in part, must find that the potential risks of participation are proportional to the potential benefits and to the Importance of the knowledge that may be learned before the IRB can approve the voluntary assumption of risk by a research participant. Adequate assessment of the risks and benefits requires careful scrutiny of the study (...)
    Download  
     
    Export citation  
     
    Bookmark   3 citations  
  • Open Label Extension Studies & the Ethical Design of Clinical Trials.David Casarett, Jason Karlawish, Pamela Sankar, Karen B. Hirschman & David A. Asch - 2001 - IRB: Ethics & Human Research 23 (4):1.
    Download  
     
    Export citation  
     
    Bookmark   3 citations